Publications by authors named "Maria Quisumbing"
Article Synopsis
- - Small cell lung cancer (SCLC) is initially responsive to chemotherapy but often relapses; this study investigated the use of gemcitabine for patients who had already undergone first-line treatment and relapsed.
- - The phase II study enrolled 27 patients with varying responses to previous chemotherapy, and despite some receiving gemcitabine, no significant tumor responses were observed—most patients continued to progress shortly after treatment.
- - The study reported that the median survival was 8.8 months for patients with sensitive disease and 4.2 months for those with refractory disease, with myelosuppression being a common adverse effect observed during treatment.
